300 related articles for article (PubMed ID: 33597857)
1. Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway.
Yan A; Song L; Zhang Y; Wang X; Liu Z
Front Aging Neurosci; 2020; 12():625166. PubMed ID: 33597857
[No Abstract] [Full Text] [Related]
2. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of BET Protein Function Suppressed the Overactivation of the Canonical NF-κB Signaling Pathway in 6-OHDA-Lesioned Rat Model of Levodopa-Induced Dyskinesia.
Wan Y; Han L; Rong L; Yang S; Song L; Wu N; Liu Z; Gan J
Front Neurosci; 2022; 16():896322. PubMed ID: 35801173
[TBL] [Abstract][Full Text] [Related]
4. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease.
Wan Y; Wu N; Song L; Wang X; Liu Z; Yuan W; Gan J
Front Aging Neurosci; 2017; 9():331. PubMed ID: 29093677
[No Abstract] [Full Text] [Related]
5. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Tronci E; Napolitano F; Muñoz A; Fidalgo C; Rossi F; Björklund A; Usiello A; Carta M
Exp Neurol; 2017 Nov; 297():73-81. PubMed ID: 28757258
[TBL] [Abstract][Full Text] [Related]
6. NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Kong M; Ba M; Liu C; Zhang Y; Zhang H; Qiu H
Behav Brain Res; 2015 Apr; 282():46-53. PubMed ID: 25576965
[TBL] [Abstract][Full Text] [Related]
7. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
[TBL] [Abstract][Full Text] [Related]
8. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
9. The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Wu N; Wan Y; Song L; Qi C; Liu Z; Gan J
Neuropsychiatr Dis Treat; 2018; 14():1779-1786. PubMed ID: 30013350
[TBL] [Abstract][Full Text] [Related]
10. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Xie CL; Wang WW; Zhang SF; Yuan ML; Che JY; Gan J; Song L; Yuan WE; Liu ZG
Sci Rep; 2014 Dec; 4():7506. PubMed ID: 25511986
[TBL] [Abstract][Full Text] [Related]
11. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
[TBL] [Abstract][Full Text] [Related]
12. Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
Kim YK; Lee AR; Park H; Yoo J; Ahn S; Jeon SH; Kim J; Park HJ
Mol Neurobiol; 2019 Apr; 56(4):2408-2423. PubMed ID: 30030752
[TBL] [Abstract][Full Text] [Related]
13. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
14. Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.
Quintana A; Sgambato-Faure V; Savasta M
Neurobiol Dis; 2012 Dec; 48(3):379-90. PubMed ID: 22759925
[TBL] [Abstract][Full Text] [Related]
15. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
16. Histological Correlates of Neuroanatomical Changes in a Rat Model of Levodopa-Induced Dyskinesia Based on Voxel-Based Morphometry.
Zhang X; Chen W; Wu Y; Zeng W; Yuan Y; Cheng C; Yang X; Wang J; Yang X; Xu Y; Lei H; Cao X; Xu Y
Front Aging Neurosci; 2021; 13():759934. PubMed ID: 34776935
[TBL] [Abstract][Full Text] [Related]
17. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
18. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
[TBL] [Abstract][Full Text] [Related]
19. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
20. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Aristieta A; Ruiz-Ortega JA; Morera-Herreras T; Miguelez C; Ugedo L
Exp Neurol; 2019 Dec; 322():113036. PubMed ID: 31425688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
